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Abstract
Background
Evidence-based medicine (EBM) has developed as the dominant paradigm of assessment
of evidence that is used in clinical practice. Since its development, EBM has been applied
to integrate the best available research into diagnosis and treatment with the purpose of im-
proving patient care. In the EBM era, a hierarchy of evidence has been proposed, including
various types of research methods, such as meta-analysis (MA), systematic review (SRV),
randomized controlled trial (RCT), case report (CR), practice guideline (PGL), and so on. Al-
though there are numerous studies examining the impact and importance of specific cases
of EBM in clinical practice, there is a lack of research quantitatively measuring publication
trends in the growth and development of EBM. Therefore, a bibliometric analysis was con-
structed to determine the scientific productivity of EBM research over decades.
Methods
NCBI PubMed database was used to search, retrieve and classify publications according to
research method and year of publication. Joinpoint regression analysis was undertaken to
analyze trends in research productivity and the prevalence of individual research methods.
Findings
Analysis indicates that MA and SRV, which are classified as the highest ranking of evidence
in the EBM, accounted for a relatively small but auspicious number of publications. For
most research methods, the annual percent change (APC) indicates a consistent increase
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in publication frequency. MA, SRV and RCT show the highest rate of publication growth in
the past twenty years. Only controlled clinical trials (CCT) shows a non-significant reduction
in publications over the past ten years.
Conclusions
Higher quality research methods, such as MA, SRV and RCT, are showing continuous pub-
lication growth, which suggests an acknowledgement of the value of these methods. This
study provides the first quantitative assessment of research method publication trends in
EBM.
Introduction
From the 1900s until now, evidence-based medicine (EBM) has developed into the dominant
paradigm for clinical practice [1–3]. Although the term EBM officially appeared for the first
time in 1992 in an article by Guyatt et al in JAMA [4], traces of the origins of EBM dated back
to ancient Greece [5,6]. By 1996, EBM was formally defined as “the conscientious, explicit and
judicious use of current best evidence in making decisions about the care of individual patients”
by Sacket et al [7] and this definition has been recognized and strongly endorsed by most of the
world's scholarly articles on EBM [8–10]. It is important to note that while often used inter-
changeably, EBM and science-based medicine (SBM) are related but different terms. SBM is a
subset of EBM which not only involves evidence for treatment efficacy but also a mechanism
by which the effect can occur. One (historical) example of a treatment that is EBM but not
SBM is a number of different forms of anaesthetic which have been clearly shown to work but
the mechanism remains unclear [11]. Internationally, EBM now provides the framework for
the diagnosis and treatment of most health conditions [12–14]. The alternative to EBM is em-
pirical diagnosis and treatment, which is a system much more open to individual, cultural and
training bias [15]. Overall this approach has become less popular as health practitioners have
greater access to cutting edge medical knowledge in the current information era. The increasing
rate of research and knowledge acquisition often means that clinicians are asked questions the
answers to which have changed since their training [16]. Patients expect physicians to be able
to interpret and explain medical information from a wide range of sources including the inter-
net [11,17]. Insurers expect physicians to know which diagnostic and treatment strategies strike
the best balance between accuracy and cost effectiveness [18]. While students need to rapidly
assess medical information and its quality, they must also learn to make decisions in the ab-
sence of good evidence [19]. EBM provides a framework for using medical and scientific evi-
dence to effectively guide clinical practice, and as such is thoroughly prepared to match all of
these challenges [4,12,19–21].
The basic principle of EBM is simply that we should treat when the evidence indicates that
perceived benefits outweigh the perceived risks and conversely not treat when the risks are
higher than the benefits. Assessments using EBM have to be conducted in 5 key steps: defining
the clinical question, finding the best evidence, critically appraising the evidence, applying the
evidence to the patient and evaluating the performance of the decision [22,23]. Finally, the evi-
dence should be presented and assessed through a logical and systematic classification in
which the value of evidence can be ranked [24]. This system allows assessment of the quality of
studies and often informs recommendation for changes in best clinical practice [25].
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There is no single, universally-accepted hierarchy of evidence [26]. Yet most people agree
that current, well-designed systematic reviews (SRV) and meta-analyses (MA) are at the least
risk of bias and hence represent the most robust, high quality evidence while case reports or ex-
pert opinions are considered having the highest risk of bias [27–31]. Other methods such as
randomized controlled trials or cohort studies fit in somewhere in the middle in terms of re-
search bias [29–33].
Despite its critical role in medical teaching, research, and clinical practice, there is a dearth
of literature measuring the interest of researchers in EBM. The contribution of published re-
search focusing on EBM over time has not been examined. Moreover, any changes in the pro-
portions of the various study methods in the EBM hierarchy remain unclarified. The current
study involved a bibliometric investigation to evaluate trends in research productivity and the
contribution of different research methods to EBM. This study used the US National Library of
Medicine’s PubMed database to find articles published over a period of 68 years (1945–2012)
sorted by journal of publication, taking advantage of the fact that PubMed facilitates filtering
by article type. This study allows quantitative assessment of the issues outlined above and high-
lights significant trends in EBM research publication.
Method
Data collection
In this study, the filter tool available as part of PubMed (http://www.ncbi.nlm.nih.gov/
PubMed) was used to search and classify all publications according to their article types with
the following strategy: typing “all [sb]” in the search field, we initially searched All PubMed
publication (APP). Searches were then limited by selecting only one of these article types: Case
Report (CR), Clinical Trial (CT), Controlled Clinical Trial (CCT), Randomized Controlled
Trial (RCT), Guideline (GL), Practical Guideline (PGL), Systemic Review (SRV) or Meta-Anal-
ysis (MA) in the filter tool. Hence, the annual number of publications of APP, CR, CT, CCT,
RCT, GL, PGL, SRV and MA were retrieved regardless of text attainability, study design, publi-
cation date, language or species. Other types of publications, which account for up to 86.94% of
APP, are neither well categorized by PubMed nor included in the hierarchical system of classi-
fying evidence, and therefore are not included in this research. The level of evidence is varied
and depends on many factors, e.g. the area that being researched, study quality, size of study
population, etc. . . [34] However, the article types which are chosen for this study are arranged,
from high to low weight of evidence according to general hierarchical order: MA, SRV, RCT,
CCT, CR [28]. The Oxford Centre for Evidence-based Medicine (OCEBM) does not mention
PGL and GL, but in other classification, they might place as the highest rank of evidence [34–
36]. Review articles were not included in this strategy because the variability within this catego-
ry would not allow non-clinical publications to be excluded. In this study, only publications
from completed years were included, as a result, all publications after 2012, which are still
being updated, were excluded. In each category, articles which did not form part of a single
continuous series of annual data points and jump-shift count possibly due to categorization
changes, as happened in cases of CR (before 1977) and CT (before 1961), were excluded.
Hence, the PubMed database search identified bibliographic details in the following time peri-
ods: 1977–2012 for CR, 1961–2012 for CT, 1966–2012 for CCT, 1966–2012 for RCT, 1973–
2012 for GL, 1978–2012 for PGL, 1945–2012 for SRV, 1990–2012 for MA, and 1945–2012 for
APP (as that is the earliest and latest date for the subgroup categories).
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Data Analysis
All data extracted were analyzed using the Joinpoint Regression Program version 4.1.0 (Statisti-
cal Research and Applications Branch, National Cancer Institute, USA) [37] to examine the
trends, and assess the significance of changes in trends, in the various study methodologies in
the EBM hierarchy. Joinpoint regression was performed to identify periods with statistically
distinct log-linear trends in number of publication of each article type over time [38–41]. The
analyses determined the joinpoints at which there is an essential change in the trends with Bon-
ferroni adjustment [42,43]. The detailed pattern of this model was first introduced and fully es-
tablished by Kim HJ and colleagues [40].
We assigned the year of publication as an independent variable and the annual number of
publications in every category and relative publication number as dependent variables for each
Joinpoint session. Within the Data File Import Wizard, we established the Delimiter box as
“Comma”, Missing Characters box as “Space”, Dependent Variable Information as “Provided”.
The number of publications (in categories such as CR, CT. . .) was set as “Count” whilst pro-
portion in each article type (such as the proportion of CT to APP) was set as “Proportion”. In
the Specifications tab, “Shift data points” was set as “0”, “Number of Joinpoints” ranged from
“0” to “3”, “Heteroscedastic Errors Option” was set at “Constant Variance”. There has been no
research on the effect of setting maximum joinpoints on the analysis results and but a number
of studies have utilized three as the maximum Joinpoints [44–46]. Therefore, we chose the
maximum number of joinpoints as 3 for the convenience when analyzing and interpreting
data. Log transformation was used for all Joinpoint analyses. In the Advance tab, the “Grid
search”method was selected and “Permutation Test” used to determine the best number of
change-points in segmented line regression. The remaining parameters were set as default.
(Fig 1)
The analyses were also conducted using SPSS version 22.0 (SPSS Inc, Chicago, IL, USA).
The software was utilized to perform a descriptive statistics of productivity of each method in
the EBM hierarchy [47,48]. An assessment of the normality of these data was retrieved by
using the software feature. SPSS allows calculation of the maximum and minimum publication
number of every article type with the corresponding years, the mean and standard deviation
(SD), or the median and interquartile range (IQR).
In this study, the main parameter Annual Percent Change (APC) was used to describe
trends. The APC was used to measure trends in medical research [40,49–52]. The APC from
year t to year (t+1) can be acquired using the following formula:
APC ð%Þ ¼ Rðtþ1Þ  Rt
Rt
 100 ¼ ðea  1Þ  100
Where Rt is the rate in year t and α is the slope coefficient in the linear equation below:
lnðRtÞ ¼ at þ b
When describing trends over a fixed pre-specified interval, a p-value 0.05 was considered
statistically significant [53,54].
Results
From the PubMed database, a total of 22,134,520 publications were extracted from the years
1945–2012. PGL and CR accounted for 0.08% and 6.75%, respectively, of APP, and comprised
the smallest and largest categories of publication. The most recent year examined (2012) had
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Fig 1. Flow chart of the data collection and analysis process.
doi:10.1371/journal.pone.0121054.g001
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the highest annual number of publications in each article type, except for CCT, which peaked
in 1997. Among all publication types, PGL accounted for the least number of total papers
(17,673 papers). RCT, SRV and MA accounted for a relatively small number of total publica-
tions (344,714 for RCT; 178,155 for SRV and 38,167 for MA). Non-RCTs accounted for
364,315 papers. (Table 1) (Fig 2).
The timeline of APC for APP presented with an initial period of striking annual increase
(APC = 75.3%, p<0.05), followed by a more sustained long period of more moderate increase
(APC = 3.0–4.8%, p<0.05) (Table 2). The APC of CR-type publications showed four periods,
in which three had continuous upward trends (APC = 4.3%, 0.8% and 4.8% in 1977–1984,
1984–2002 and 2002–2007, respectively, p<0.05) when one remained steady (APC = 0.8% in
2007–2012 p>0.05). Other types of article manifested increasing trends in number of papers
during the recorded period. The exception was CCT, which had no significant change in the
most recent fourteen years (APC = -2.56%, p>0.05). SRV and MA had continuous upward
trends in the number of publications (APC of SRV = 3.3%, 23.6% and 12.2% in 1945–1970,
1970–1999 and 1999–2012, respectively; and APC of MA = 8.2% in 1990–1996 and 16.9% in
1996–2012, p<0.05).
The proportion of CT, SRV and MA publications to APP publications has been increasing
significantly during the most recent joinpoint period (APC of CT/APP, SRV/APP and MA/
APP is 4.0%, 7.1% and 11.7%, respectively, with p<0.05). The CCT/APP and CR/APP propor-
tion showed a downward trend in 1999–2012 (CCT/APP, APC = -7.1%, p<0.05) and 2007–
2012 (CR/APP, APC = -4.4%, p<0.05) while other proportions including RCT/APP, GL/APP,
PGL/APP show no significant change (p>0.05).
The proportion of CCT to CT had been exhibiting a gradually declining trend during the
observed period from 1966 to 2012 (APC = -5.1%, p<0.05). The proportion of RCT to CT
showed a different pattern: the number of publications rose continuously in 1966–1992 as well
as in 1996–2012 (period 1966–1981: APC = 9.8%; 1981–1992: APC = 2.7% and 1996–2012:
Table 1. Evidence-based Medicine publications 1945–2012.
Method Year
range
Total
publication
Max (year) Min (year) Median +IQR
All Pubmed
publication
1945–
2012
22134520 926293
(2012)
20242 (1945) 275347 330184.5
Case report 1977–
2012
1494328 55927
(2012)
27430 (1977) 39803.5 8713.8
Clinical Trial 1961–
2012
709029 40890
(2012)
1 (1962) 8095 21149.5
Controlled clinical trial 1966–
2012
85652 3302 (1997) 616 (1966) 1700 1244
Randomized controlled
trial
1966–
2012
344714 22058
(2012)
194(1966) 5647 10725
Guideline 1973–
2012
23590 1398 (2012) 1
(1973,1977)
646.5 1091
Practice guideline 1978–
2012
17673 1235 (2012) 1 (1978) 452 951
Systematic
review
1945–
2012
178155 21968
(2012)
1 (1945) 86.5 2237.3
Meta-analysis 1990–
2012
38617 6500 (2012) 272 (1990) 948 2168
+IQR: Interquartile Range
doi:10.1371/journal.pone.0121054.t001
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APC = 1.1%, p<0.05) while in 1992–1996 declined, but fell short of statistical significance
(APC = -7.07%, p>0.05). The proportion of PGL/GL showed rising trends during two time pe-
riods (1978–1987: APC = 9.1%, p<0.05; and 1991–1994: APC = 63.2%, p<0.05) with a down-
ward trend during the intervening period (1987–1991, APC = -34.4%, p<0.05). In recent years,
the PGL/GL proportion has remained unchanged (APC = 0.6%, p>0.05).
Fig 2. (A) Stacked area chart displaying the order of appearance and the trends of development of CR,
CT, GL, SRV and MA regarding number of publications in PubMed over some time periods. (B)
Stacked area chart displaying the order of appearance and the trends of development of RCT, CCT and PGL
regarding number of publications in PubMed over some time periods
doi:10.1371/journal.pone.0121054.g002
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Discussion
This study demonstrates that article types with higher levels of evidence accounted for fewer
publications than those with lower levels of evidence. One possible reason for this observation
is that systematic review (SRV), randomized controlled trial (RCT), and meta-analysis (MA)
articles may take longer to publish because of the time needed for establishing study design,
data collection and analysis, as well as for peer review [55–57]. These article types also need
Table 2. JoinPoint regression analysis of different APC trends.
Method Trend 1 Trend 2 Trend 3 Trend 4
Years jAPC Years jAPC Years jAPC Years jAPC
All Pubmed
publication
1945–
1947
75.3* 1947–
1971
4.8* 1971–
2002
3.0* 2002–
2012
5.1*
Case report 1977–
1984
4.3* 1984–
2002
0.8* 2002–
2007
4.8* 2007–
2012
0.8
Case report/ All
Pubmed publication
1977–
1982
2.1* 1982–
2004
-1.9* 2004–
2007
0.7 2007–
2012
-4.4*
Clinical Trial 1961–
1963
98.1* 1963–
1966
566.2* 1966–
2012
7.4*
Clinical Trial/ All
Pubmed publication
1961–
1963
79.1* 1963–
1966
514.9* 1966–
2012
4.0*
Controlled clinical trial 1966–
1998
3.6* 1998–
2012
-2.6
Controlled clinical trial/ All
Pubmed publication
1966–
1999
0.5 1999–
2012
-7.1*
Controlled clinical trial/
Clinical Trial
1966–
2012
-5.1*
Randomized controlled trial 1966–
1973
15.8* 1973–
1976
31.0* 1976–
1992
12.6* 1992–
2012
4.9*
Randomized controlled trial/
All Pubmed publication
1966–
1971
11.1* 1971–
1979
18.3* 1979–
1995
7.8* 1995–
2012
0.2
Randomized controlled trial/
Clinical Trial
1966–
1981
9.8* 1981–
1992
2.7* 1992–
1996
-7.1 1996–
2012
1.1*
Guideline 1973–
1983
11.2* 1983–
1991
84.0* 1991–
2012
4.2*
Guideline/ All Pubmed
publication
1973–
1983
7.8 1983–
1991
79.0* 1991–
2012
0.4
Practice guideline 1978–
1994
48.6* 1994–
2012
5.6*
Practice guideline/ All
Pubmed publication
1978–
1994
44.4* 1994–
2012
1.5
Practice guideline/
Guideline
1978–
1987
9.1* 1987–
1991
-34.4* 1991–
1994
63.2* 1994–
2012
0.6
Systematic review 1945–
1970
3.3* 1970–
1999
23.6* 1999–
2012
12.2*
Systematic review/ All
Pubmed publication
1945–
1970
-2.5* 1970–
1999
20.2* 1999–
2012
7.1*
Meta-analysis 1990–
1996
8.2* 1996–
2012
16.9*
Meta-analysis/ All
Pubmed publication
1990–
1995
5.9* 1995–
2012
11.7*
jAPC = Annual percent changes calculated by JoinpointRegression Analysis
*APC is significantly different from zero when P < 0.05
doi:10.1371/journal.pone.0121054.t002
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more financial, technical and human resources to conduct. Data for SRV and MA are collected
from available clinical trials, cohort studies, case-control studies, observational studies, etc.
[55,56]. Additionally SRVs and MAs can only occur after a sufficient body of research has been
undertaken which may take years if not decades. As a result of their inherent design, SRV and
MA will mostly be produced at a much lower rate than other publication types which are
ranked as having a lower quality of evidence. Similar to the case of SRV, RCT and MA, publish-
ing practice guideline (PGL) is also time-consuming because of the time it takes to manage
conflicts of interest, to assess the quality of evidence and to facilitate the consensus [58]. Case
reports (CR) are ranked as being of the lowest quality of evidence but are nonetheless impor-
tant for generating hypotheses for further studies to resolve new issues [37,59,60].
The overall slightly positive value of annual percent change (APC) for SRV and the negative
APC in the proportion of SRV to All PubMed publication (APP) suggested that SRV has had a
long period of slow growth and a decrease in popularity in the scientific world. However, since
1970, the APCs for SRV and the APCs in the proportion SRV/APP have increased dramatical-
ly. This increment might reflect a regain of interest in SRV among scientists. This may have
been due to the reconsideration of the role of SRV as a critical contributor to Evidence-based
Medicine (EBM) [61,62].
The marked increase in the APCs for MA, as well as the APCs for the proportion of MA to
APP, suggests that MA is a popular methodology for publication in modern EBM. As a subset
of SRV, MA uses a method that aims at combining results from several studies mathematically
and hence create a larger sample size [55,56]. Combining data helps researchers assess more ac-
curately the strength of relationship of two variables, enhances the statistical power of analysis,
and narrows down the confidence interval. MA first appeared as recently as 1990, and have of-
fered a number of advantages, including establishing a new benchmark in the quality
of evidence.
For PGL, the growth was initially very strong (APC = 48.6%), but for the most recent 20
years, the growth rate has been slow (APC = 5.6%). As mentioned above, the recorded period
for PGL was relatively short, and PGL currently has the lowest total number of publications. In
the initial phase of growth, PGL appeared with a very small number of publications. Many
questions have been raised about the quality of PGL. Initially some PGLs were assembled on
consensus of expert committees rather than based on research derived evidence [63–66]. Clini-
cal application of PGL was also an emerging problem for PGL makers [64,65,67]. The estab-
lishment of standardized criteria for developing PGL, beginning with the criteria of the
Institute of Medicine (IOM) in 1990, opened a new era in which more focus was placed on
strengthening recommendations through strong evidence, and translating evidence into con-
cise instructions for clinical practice [68]. This fact may explain why the growth rate of PGL
has decreased over the past 20 years.
This study found a slight increase in growth in the number of published clinical trials (CTs)
((APC = 7.4% for CT). As mentioned earlier, CT is still important for generating hypothesis
and creating data for further in-depth studies, namely SRV and MA. We hypothesize that as
APP continues to grow in number, the aforementioned article types will continue to increase,
as the scientific community will continue to face new issues and open up to new perspectives.
RCTs are more prevalent than controlled clinical trial (CCTs), as shown by their respective
total absolute quantities (Table 1), the stable APCs in the proportion RCT/CT and the reduc-
tion in the APCs in CCT/CT (Table 2). Methods used in RCT offers advantages such as a re-
ducing effect on biases and errors as well as the establishment of a strong statistical power, and
enable scientists to obtain high-quality evidence and valuable data for SRVs and MAs [69].
Nowadays, RCT is used extensively in most Phase III and some phase II clinical trials [69,70].
CT had very large APCs in the 1960’s. This marked increase may be explained by significant
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changes in the definition of CT during the 1950s [71]. After this period, plenty of treatment
methods were invented and proved effectiveness by using CT method. Besides, the promotion
for CT, which has been seen in that era as the gold standard for clinical studies, the most elo-
quent proof for the treatment effectiveness, had somewhat supported the rapid growth in the
number of publications in this article type.
The aim of this study was to assess the tendency of changes in quantities of publication
types which are used in evidence-based medicine, and thus to partly show researchers’ interest
in various publication types. We considered some publication types such as MA, SRV, RCT as
providing high level of evidence; however, according to OCEBM 2011 [34], the level of evi-
dence may be downgraded because of study quality, impreciseness, indirectness, too small ab-
solute sample size or inconsistency between studies. Further studies are required to analyze the
effect of publication types on EBM, especially with qualitative approaches. The current study
utilized data derived from the Medical Subject Headings (MeSH) system of PubMed; therefore,
available studies which are not included in MeSH are not included in our analysis. Some of the
year ranges were not significant maybe because of the short examined regression segment.
Conclusion
In conclusion, quantitative growth was found across all publication types. The growth of all,
rather than only some publication types, is necessary for the development of EBM, because evi-
dence-based medicine develops in a step-by-step manner: evidence from low-quality studies
serve as data points for conducting larger/better designed studies which provide stronger evi-
dence. Current trends may predict that SRV and MA will continue to grow in the future. RCT
is getting priority over the other subset of CT; and although the proportion of RCT to CT has
recently shown a stable but significantly increasing trend, RCT is still important in order to
gain valuable robust evidence needed for better health care outcomes. This current study pro-
vides the first large scale quantitative analysis of EBM publication trends.
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